Kaplan Gilla

Kaplan Gilla is listed in filings as Director at Avalo Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jun 4, 2026, including sale activity. Recent filings connect the profile to Avalo Therapeutics, Inc. (AVTX) and Tyra Biosciences, Inc. (TYRA). The current snapshot covers public activity from Jun 18, 2024 to Jun 4, 2026. Reported amounts are shown as $280.6K to $119.6K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.